Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles
Author(s)
Vu Han, Tu-Lan; Balkanska-Sinclair, Elena; Floyd, Scott R; Lam, Fred Chiu-Lai; Morton, Stephen Winford; Wyckoff, Jeffrey; Vu-Han, Tu-Lan; Hwang, Mun Kyung; Maffa, Amanda; Yaffe, Michael B; Hammond, Paula T; ... Show more Show less![Thumbnail](/bitstream/handle/1721.1/116978/s41467-018-04315-4.pdf.jpg?sequence=6&isAllowed=y)
Downloads41467-018-04315-4.pdf (2.504Mb)
PUBLISHER_CC
Publisher with Creative Commons License
Creative Commons Attribution
Terms of use
Metadata
Show full item recordAbstract
Effective treatment for glioblastoma (GBM) is limited by the presence of the blood-brain barrier (BBB) and rapid resistance to single agent therapies. To address these issues, we developed a transferrin-functionalized nanoparticle (Tf-NP) that can deliver dual combination therapies. Using intravital imaging, we show the ability of Tf-NPs to traverse intact BBB in mice as well as achieve direct tumor binding in two intracranial orthotopic models of GBM. Treatment of tumor-bearing mice with Tf-NPs loaded with temozolomide and the bromodomain inhibitor JQ1 leads to increased DNA damage and apoptosis that correlates with a 1.5-to 2-fold decrease in tumor burden and corresponding increase in survival compared to equivalent free-drug dosing. Immunocompetent mice treated with Tf-NP-loaded drugs also show protection from the effects of systemic drug toxicity, demonstrating the preclinical potential of this nanoscale platform to deliver novel combination therapies to gliomas and other central nervous system tumors.
Date issued
2018-05Department
Massachusetts Institute of Technology. Department of Biological Engineering; Massachusetts Institute of Technology. Department of Biology; Massachusetts Institute of Technology. Department of Chemical Engineering; Koch Institute for Integrative Cancer Research at MITJournal
Nature Communications
Publisher
Nature Publishing Group
Citation
Lam, Fred C. et al. “Enhanced Efficacy of Combined Temozolomide and Bromodomain Inhibitor Therapy for Gliomas Using Targeted Nanoparticles.” Nature Communications 9, 1 (May 2018): 1991 © 2018 The Author(s)
Version: Final published version
ISSN
2041-1723